Human safety, efficacy, dosing, and clinical utility havent been established
This is consistent with a diagnosis of macrocytic anemia
Known and theoretical safety concerns include: Retatrutide (and the GLP-1 receptor agonist class): Nausea, vomiting, diarrhoea, and reduced appetite are the most commonly reported side effects
When AOD-9604 binds to or modulates these receptors, it preferentially activates fat cells while having minimal effects on other tissues that primarily express beta-1 and beta-2 adrenergic receptor subtypes
Certificates of Analysis and product documentation are shown with product details when available
Its key to teach patients about B12-rich foods like meat, fish, and dairy